Kedrion Biopharma is proud to participate in ESID 2024, a key global event centered on Primary Immunodeficiency (PID).
As a company committed to supporting patients with rare diseases, Kedrion continues to champion the PID community. Our long-standing partnership with the International Patient Organization for Primary Immunodeficiencies (IPOPI) is a testament to our shared commitment to improving lives.
IPOPI PID Champion Awards was a prestigious ceremony, held on October 17th during the XVIII IPOPI Global Patients Meeting, held on the same days of the ESID 2024 Conference. Supported by Kedrion with an unconditional grant, the Award ceremony was an occasion to honor individuals who have made exceptional contributions to support the PID community.
“The IPOPI Global Patient Meeting is more than just a gathering; it’s a catalyst for change. We empower patient leaders worldwide, fostering a stronger community through learning, sharing, and networking. But a community also needs its rituals, thus our IPOPI PID Champions Awards ceremony. An IPOPI Award is a collective acknowledgment by the IPOPI family of an individual’s or a team’s impact, dedication, and value to our community. This is what makes them so special. Kedrion’s generous support enables us to elevate this awards ceremony to something truly extraordinary, a night filled with inspiration, pride, and shared joy.” stated Martine Pergent, IPOPI President.
“At Kedrion we recognize that living with a Primary Immunodeficiency is not just a medical condition; it’s a journey that profoundly impacts lives, families, and loved ones. We are honored to be a part of the journey. Only by working together we can effectively address the unmet needs of PID patients.” said Ugo di Francesco, CEO at Kedrion Biopharma.
Kedrion was present at ESID 2024 with many key activities. These included a booth where attendees learned about the company’s ongoing work to improve access to care and support for PID patients, and poster presentations.
One poster was titled “How early diagnosis can be improved in Primary Immunodeficiency (PID): the first Italian-Turkish joint workshop” presented by Dr. Nazlı Deveci Demirbaş.
Finally, our international delegation, comprising healthcare professionals and patient association representatives from Italy, Serbia, Poland, Turkey, and Portugal, reflected our commitment to global collaboration in the field of PID care.
Kedrion’s active role at ESID 2024 reinforces its commitment to partnering with healthcare professionals, patient organizations, and advocates to ensure that those with PIDs receive the care and treatment they need for healthier lives.
The importance of early diagnosis in Primary Immunodeficiency
Primary Immunodeficiencies (PIDs) are genetic disorders that compromise the immune system, making individuals susceptible to infections. While some cases are mild, others can lead to severe, recurring infections if undiagnosed. Despite affecting millions, 70-90% of people with PIDs remain undiagnosed. Raising awareness and promoting early diagnosis is crucial for preventing complications and improving patient outcomes through treatments like immunoglobulin (IG) therapy.(1)
(1) https://worldpiweek.org/what-is-primary-immunodeficiency-pi/